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The vascular system fulfils the oxygen and nutrient require-ments of tissues and organs, whilst maintaining tissue 
growth and repair. Vasculogenesis is a highly orchestrated 
process in embryonic development where de novo vessel for-
mation takes place from angioblasts, the endothelial precur-
sor cells.1 Subsequent sprouting from existing vessels, that is 
angiogenesis, leads to a vascular network of arteries, veins, and 
capillaries. In adult organisms, this process is quiescent; how-
ever, endothelial cells retain their capacity to differentiate into 
new vessels in response to angiogenic signals when required. 
Angiogenesis is deregulated in disease states; it is inadequate 
in diseases, such as stroke, ischemia, and diabetic wound heal-
ing2 and excessive in cancer, inflammatory disorders, and eye 
diseases,3,4 thus, offering tremendous scope for therapeutic 
intervention.4 Many pro- and antiangiogenic strategies have 
been developed; although the proangiogenic approaches have 
not been successful to date, antiangiogenic therapies have been 
moderately effective in the treatment of cancer and eye dis-
eases.5 Clinically approved antiangiogenic anticancer agents 
primarily target the VEGF pathway and have many limitations, 
such as increased resistance, toxicity,6 secondary metastases,7 
and limited efficacy in certain cancer types, highlighting the 
need for novel agents targeting alternative pathways.
FK506-binding protein like (FKBPL), a novel member of 
the immunophilin protein family,8,9 is a potent secreted anti-
angiogenic protein10,11 targeting the CD44 pathway.12 FKBPL 
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Objective—The antitumor effects of FK506-binding protein like (FKBPL) and its extracellular role in angiogenesis are 
well characterized; however, its role in physiological/developmental angiogenesis and the effect of FKBPL ablation has 
not been evaluated. This is important as effects of some angiogenic proteins are dosage dependent. Here we evaluate the 
regulation of FKBPL secretion under angiogenic stimuli, as well as the effect of FKBPL ablation in angiogenesis using 
mouse and zebrafish models.
Approach and Results—FKBPL is secreted maximally by human microvascular endothelial cells and fibroblasts, and this 
was specifically downregulated by proangiogenic hypoxic signals, but not by the angiogenic cytokines, VEGF or IL8. 
FKBPL’s critical role in angiogenesis was supported by our inability to generate an Fkbpl knockout mouse, with embryonic 
lethality occurring before E8.5. However, whilst Fkbpl heterozygotic embryos showed some vasculature irregularities, 
the mice developed normally. In murine angiogenesis models, including the ex vivo aortic ring assay, in vivo sponge 
assay, and tumor growth assay, Fkbpl+/− mice exhibited increased sprouting, enhanced vessel recruitment, and faster 
tumor growth, respectively, supporting the antiangiogenic function of FKBPL. In zebrafish, knockdown of zFkbpl using 
morpholinos disrupted the vasculature, and the phenotype was rescued with hFKBPL. Interestingly, this vessel disruption 
was ineffective when zcd44 was knocked-down, supporting the dependency of zFkbpl on zCd44 in zebrafish.
Conclusions—FKBPL is an important regulator of angiogenesis, having an essential role in murine and zebrafish 
blood vessel development. Mouse models of angiogenesis demonstrated a proangiogenic phenotype in Fkbpl 
heterozygotes.  (Arterioscler Thromb Vasc Biol. 2015;35:845-854. DOI: 10.1161/ATVBAHA.114.304539.)
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is also a prognostic biomarker for breast cancer and predictive 
for endocrine therapy.13,14 Therapeutic peptide derivatives of 
FKBPL, AD-01 and ALM201, have highly potent antiangio-
genic activity, and because of their CD44-mediated effect, these 
agents are also able to target CD44-positive cancer stem cells,15 
further strengthening their therapeutic potential. Following 
extensive preclinical validation, ALM201 has now completed 
toxicological evaluation in preparation for phase I clinical trials 
in cancer patients. Although the robust antiangiogenic effects 
of FKBPL and its therapeutics have been well characterized, 
the role of endogenous FKBPL in physiological and develop-
mental angiogenesis is not. Here we address these questions 
using cell lines, knockout (KO) mice, and zebrafish models. 
We have developed an Fkbpl heterozygote mouse model and 
characterized the functional role of FKBPL in a range of in 
vivo and ex vivo angiogenesis end points. Furthermore, we 
have used GFP-zebrafish that provides an easy and strong 
model for evaluating developmental angiogenesis.16 We report 
that the antiangiogenic protein, FKBPL, plays a critical role 
in embryonic development, and its secretion is regulated by 
hypoxia. Fkbpl heterozygous mice upregulated angiogenesis 
in all models evaluated, strengthening the biological role of 
FKBPL in angiogenesis and supports FKBPL-based diagnostic 
and therapeutic interventions as they advance to clinical trials.
Materials and Methods
Materials and methods are available in the online-only Data 
Supplement.
Results
FKBPL Secretion Is Regulated by Hypoxia
We have previously reported that extracellular FKBPL exerts its 
antimigratory effects via CD44, and this effect can be reversed 
using a blocking antibody specific to the active angiogenic site of 
Nonstandard Abbreviations and Acronyms
FKBPL FK506-binding protein like
KO knockout
MO morpholino
Figure 1. Regulation of FK506-binding protein like (FKBPL) secretion. A, ELISA demonstrating that FKBPL was maximally secreted 
by endothelial (HMEC-1) and fibroblast (AGO-1522) cell lines, in comparison to tumor cell lines, and B, its secretion was specifically 
downregulated under hypoxia in HMEC-1 cells; intracellular protein (C) or mRNA (D) levels assessed by qRT-PCR did not change. Pro-
angiogenic cytokines, VEGF, 25 ng/mL, or IL8, 1 nmol/L, did not alter FKBPL secretion (E) or intracellular (F) levels. A log phase 24 h old 
monolayer was subjected to different oxygen tensions or cytokine treatments for 24 h and the spent medium; RNA and protein from cell 
lysates were harvested. FKBPL levels were quantified by ELISA of 50-fold concentrated spent medium and normalized to cell number at 
the time of harvest. Data points are mean±SEM. n≥3. **P<0.01 paired t test.
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FKBPL.12 When secreted levels of FKBPL from various cell lines 
were evaluated by ELISA, maximal secretion (15–20 ng/107 cells 
and ≈7 ng/107 cells) was observed in endothelial cells, human 
microvascular endothelial cells (HMEC-1), and normal human 
fibroblasts, AGO-1552, respectively. Cancer cell lines or the 
normal breast epithelial cell line, MCF10A, secreted lower lev-
els, ≤1.5 ng/107 cells (Figure 1A). The secretion from HMEC-1 
was specifically inhibited when cells were cultivated in a proan-
giogenic hypoxic environment (0.1% O
2
) for 24 h (Figure 1B), 
whereas FKBPL mRNA or intracellular FKBPL protein levels 
remained unchanged (Figure 1C and 1D). HIF-1 increased upon 
hypoxic stimulation, acting as a positive control. Other proangio-
genic stimulators, such as VEGF, IL-8, and bFGF, did not sig-
nificantly alter FKBPL secretion, protein or mRNA expression 
(Figure 1E and 1F; Figure I in the online-only Data Supplement). 
Having established that FKBPL secretion was inhibited by proan-
giogenic hypoxic signaling, we proceeded to evaluate its endog-
enous role in development and pathological angiogenesis using 
knockout models.
Fkbpl Heterozygous Knockout Mice Appear Normal 
but Homozygous Knockout Is Embryonically Lethal
The Fkbpl-targeted allele was deleted in the exon 2 region 
(Figure IIAi and IIAii in the online-only Data Supplement) 
and following germline transmission resulting progeny were 
genotyped; the presence of one band at 744 bp corresponded 
to Fkbpl wildtype allele and an additional band at 526 bp 
corresponded to the Fkbpl-targeted allele (Figure 2Ai). 
Intercrossing of Fkbpl+/neo mice did not yield any Fkbplneo/
neo mice, with over 50 progeny, indicating that the homozy-
gous KO of Fkbpl was embryonically lethal. The Fkbpl+/neo 
mice retained the neomycin selective marker; therefore, to 
exclude any interference from expression of this marker, it 
was deleted using CREtg/+ mice with 2 sequential crosses 
with Fkbpl+/neo mice to obtain Fkbpl+/− mice (Figure IIAiii 
in the online-only Data Supplement) that were genotyped 
to confirm the presence of 2 bands at 537 and 240 bp for 
Fkbpl+/− mice and a single band at 240 bp identifying the 
Fkbpl+/+ mice (Figure 2Aii). Subsequently, embryos from 
timed matings were analyzed at E8.5-E13. The presence 
of empty yolk sacs and resorbed embryos was observed at 
E8.5 and E9.5 (Figure 2Aiii), suggesting lethality within the 
Fkbplneo/neo line, confirmed by genotyping of the yolksacs 
(Figure 2Aiii); intact Fkbpl+/neo embryos did not demonstrate 
any gross phenotypic changes. Embryonic lethality was 
also confirmed in the Fkbpl−/− mice because of the inabil-
ity to obtain Fkbpl−/− mice with several (>50) intercrosses of 
Fkbpl+/− mice.
Figure 2. Fkbpl knockout mice and embryo characterization. A, Genomic PCR of (i) Fkpbl+/neo (lanes 1–4) heterozygotes and Fkpbl+/+ liter-
mate controls (lane 5) and (ii) Fkpbl+/− (lanes 1–3) and Fkpbl+/+ (lane 4) genotypes. (iii) Timed matings of the Fkpbl heterozygous crosses, 
demonstrating E9.5 embryos showing empty or resorbed yolk sac (arrows) and genotyping of the embryonic yolk sac; Fkpbl+/+ (lane 1.8), 
Fkpbl+/neo (lanes 1.1–1.4, 1.9) and Fkpblneo/neo (lanes 1.5–1.7; boxed) alleles. Homozygous Fkpblneo/neo knockout corresponded to resorbed 
embryos. B, FK506-binding protein like (FKBPL) expression in adult mice (i) real-time quantitative PCR analysis of RNA from tissue lysates 
of murine organs, validating the effect of genomic knockdown on Fkbpl mRNA and (ii) ELISA of serum for secreted FKBPL; reduced lev-
els in Fkbpl+/neo and Fkbpl+/− mice in comparison to their Fkbpl+/+ littermates. Murine organs were harvested in RNAlater, followed by RNA 
extraction qPCR quantification. Serum was collected from age-matched mice bleeds. Data points are mean±SEM. n≥3. *P<0.05, **P<0.01, 
***P<0.001 (B(i) unpaired t-tests and B(ii) 1-way ANOVA, Tukey multiple comparison). C, Expression of FKBPL and endomucin in interso-
mitic vessels of Fkbpl+/+ and Fkbpl+/neo mice at E11.5. Transverse sections at the level of an intersomitic vessel showing merged images of 
FKBPL expression in Fkbpl+/+ embryo (a, 40×; b, 63×, magnification), single channel (ai, bi) FKBPL (green) and (aii, bii) endomucin (red). 
FKBPL is strongly expressed in endomucin+ve cells (yellow merge; small arrows) and in nucleated rounded cells, in the lumen of blood ves-
sels (big arrows). Intersomitic vessels show stereotypical pattern. Merged images (c, d) showing reduced FKBPL expression in a cluster of 
round nucleated cells located within the lumen of an endomucin+ve intersomitic blood vessel in Fkbpl+/neo mice. Intersomitic vessels show 
normal pattern but seem locally distended by cluster of intraluminal cells (big arrow). Single channel images: (ci) FKBPL (green) and (cii) 
endomucin (red). All slides were counterstained with DAPI (blue). Scale bar=50 μm in a and c, 40× and 10 μm in b and d, 63×.
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Fkbpl+/neo mice were then further characterized. Genomic 
KO of one Fkbpl allele resulted in ≈2-fold reduction of Fkbpl 
mRNA in all organs analyzed (Figure 2Bi). Reduced levels of 
Fkbpl expression because of loss of one allele was also con-
firmed in the Fkbpl+/− mice (Figure IIC in the online-only Data 
Supplement). However, serum FKBPL levels were downregu-
lated up to 4-fold in the Fkbpl+/neo or Fkbpl+/− mice in compari-
son to Fkbpl+/+ littermates (Figure 2Bii); there was no significant 
difference in FKBPL levels between Fkbpl+/neo or Fkbpl+/− mice. 
The Fkbpl+/neo and Fkbpl+/− mice developed normally with no 
overt abnormalities, and the organ histology appeared normal 
(Figure IIB in the online-only Data Supplement).
Embryonic Expression of FKBPL 
and Effects on Vasculature
During early development (E11.5), FKBPL was strongly 
expressed in endothelial (endomucin+) cells of the blood 
vessels, as shown by yellow (red–green merged) stain-
ing (Figure 2Ca and 2Cb, small arrows), consistent with 
Figure 1A. FKBPL was also expressed in nucleated rounded 
cells located within blood vessels (Figure 2Ca and 2Cb, 
big arrows; video in the online-only Data Supplement). 
Additionally, FKBPL was expressed in many other cell types, 
as an intense subcellular spot, closely associated with the 
nucleus (Figure 2Ca and 2Cb, small arrows). In accordance 
with the qPCR data presented in Figure 2Bi, heterozygote 
mice showed reduced FKBPL immunostaining (Figure 2Cc 
and 2Cd). Interestingly, accumulation of rounded FKBPL+ 
cells was often seen within the blood vessels of Fkbpl+/neo  
embryos (Figure 2Cc and 2Cd, big arrow). However, this 
did not affect the overall development of the Fkbpl+/neo mice 
because the new born and adult mice appeared normal.
Increased Ex Vivo Sprouting of Aortae 
in Fkbpl Heterozygotic Mice
Further characterization of Fkbpl KO in angiogenesis was per-
formed by assessing the effect on aortic sprouting ex vivo. The 
aortae from Fkbpl+/neo mice showed enhanced sprouting and 
disordered branching (Figure 3A). Quantification revealed a 
statistically significant increase (≈2 fold) in vessel branching 
and vessel length (Figure 3B). The endothelial origin of the 
sprouts was confirmed by staining aortic rings with endomucin 
(Figure IV in the online-only Data Supplement). The Fkbpl+/+ 
littermates showed an identical phenotype in the aortic sprout-
ing to that of WT C57Bl6 mice as expected (Figure IIIA in 
the online-only Data Supplement). Fkbpl+/− aortae showed an 
Figure 3. FK506-binding protein like (FKBPL) regulates ex vivo sprouting of vessels from mouse aorta. Representative photomicro-
graphs (A) and vessel measurements (B) of aortic rings showing enhanced sprouting of vessels from the Fkbpl+/neo aortae in comparison 
to Fkbpl+/+ aortae, C, Inhibition of sprouting mediated by AD-01 (100 nmol/L). D, Additive effect of VEGF (30 ng/mL) treatment on vessel 
sprouting in Fkbpl+/+ and Fkbpl+/neo aortae. Sliced, excised aortae were embedded into matrigel±AD-01 or VEGF and vessel sprouting 
evaluated microscopically after 10 days. Data points are mean±SEM. n≥3. *P<0.05, ***P<0.001 (1-way ANOVA, C, D; Tukey multiple com-
parison post tests).
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enhanced pattern of sprouting identical to Fkbpl+/neo aortae 
(Figure IIIB in the online-only Data Supplement), indicating 
that the 2 murine Fkbpl+/neo and Fkbpl+/− strains have a similar 
phenotype. To demonstrate that this was caused by a reduction 
in the levels of the antiangiogenic protein, FKBPL, AD-01, the 
therapeutic peptide derived from the antiangiogenic domain 
of FKBPL, was added to the assay conditions. As expected, 
this abrogated the enhanced sprouting observed in Fkbpl+/neo 
aortae because of restoration of the FKBPL antiangiogenic 
function by complementing the activity levels. The angiogenic 
activity of the Fkbpl+/+ aortae was also significantly inhibited 
as expected (Figure 3C). Treatment of the aortic rings with 
VEGF enhanced the sprouting of Fkbpl+/+ aortae and had an 
additive enhancement effect on Fkbpl+/neo aortae (Figure 3D), 
suggesting that FKBPL-mediated sprouting is independent of 
VEGF angiogenesis pathway.
Fkbpl Heterozygous Mice Support Enhanced 
Vessel Recruitment In Vivo in the Sponge Assay
The effect of Fkbpl ablation was further assessed in vivo in a 
sponge assay. Polyether sponges were implanted into Fkbpl+/neo, 
Fkbpl+/−, and Fkbpl+/+ mice, and microvessel recruitment 
was stimulated with bFGF. H&E stained sections of sponges 
from Fkbpl+/neo mice had a significantly higher number of small 
(40%) and big (50%) vessels (Figures 4A and 4B). The endo-
thelial specificity of this effect was further confirmed using 
endomucin staining; a significantly higher number (15% to 
20%) of endomucin-stained vessels were observed in sponges 
from Fkbpl+/neo (P<0.05) and Fkbpl+/− (P<0.005) in compari-
son to the Fkbpl+/+ littermates. This enhanced angiogenesis, 
however, also corresponded with an increase in the number of 
erythrocytes leaking into the surrounding tissue (Figures 4E 
and 4F), indicating that vessels within FKBPL-deficient mice 
may be less robust.
Higher Tumor Growth Rate and Tumor 
Angiogenesis in Fkbpl Heterozygous Mice
Role of Fkbpl ablation in pathological angiogenesis was eval-
uated in the syngeneic Lewis lung carcinoma tumor model. 
Lewis lung carcinoma cells grown on the rear dorsum of 
Fkbpl+/neo or Fkbpl+/− mice had an increased growth rate in 
comparison to the Fkbpl+/+ littermates (Figure 5A), corre-
sponding to a significantly shorter survival, defined as time 
to reach >600 mm3 in tumor volume (Figure 5B) in the Fkbpl 
Figure 4. Increased vessel recruitment and vessel leakage in polyether sponges implanted in Fkbpl+/neo mice in comparison to Fkbpl+/+ 
littermates. Demonstrative H&E images of sponge sections; arrows highlighting the vessels (A), vessel quantification on H&E stained 
sponge sections (B); representative images of endomucin stained (brown) sponge sections (C); quantification of endomucin stained ves-
sels in sponge sections (D); images showing the different levels of blood leakage in H&E stained sections (E); quantification of blood 
leakage in H&E stained sections (F). Subcutaneously implanted polyether sponges were treated with murine bFGF for 15 days, excised, 
formalin fixed, paraffin embedded, and stained with H&E or antiendomucin antibody. Data points are mean±SEM. n≥3. *P<0.05, **P<0.01, 
***P<0.001 (B, unpaired t test; D, 1-way ANOVA, Tukey multiple comparison post tests).
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heterozygotes. Immunohistology of the tumors for CD31 
expression was performed to assess the effect on tumor vascu-
lature; an increase in CD31-stained blood vessels (Figure 5C) 
was observed in Fkbpl+/neo and Fkbpl+/− mice. Gross exami-
nation of the blood vessels suggested an irregular structure, 
with the endothelium appearing thicker and less organized in 
tumors grown in Fkbpl+/neo and Fkbpl+/− mice in comparison to 
a well-defined and ordered vasculature in Fkbpl+/+ littermates 
(Figure 5D): a feature of enhanced angiogenesis.
Fkbpl Regulates Developmental 
Angiogenesis in the Zebrafish
Having established that KO of one allele of Fkbpl produced 
a proangiogenic phenotype in a range of murine assays, we 
proceeded to evaluate this effect in zebrafish. NCBI Standard 
Protein Blast analysis identified Similar to WAF-1/CIP1 stabi-
lizing protein 39 isoform 2 (GenBank ID: XP_001923918.1) 
as the zebrafish orthologue to the human FKBPL pro-
tein (GenBank ID: NP_071393.2). ClustalW2 alignment 
showed 27% identity between the 2 sequences (Figure VA 
in the online-only Data Supplement). Analysis of the pro-
tein domains using SMART (Simple Modular Architecture 
Research Tool) showed a similar structure in the C-terminal 
tetra-trico peptide repeat (TPR) domains, typical of almost all 
FKBP family members (Figure VB in the online-only Data 
Supplement).
Microinjection of AD-01 into zebrafish embryos at 72 hpf 
inhibited the intersegmental vessels (Figure 6A), whereas 
scrambled AD-01 did not affect the vasculature and showed 
a similar pattern to uninjected embryos. Vessel abnormalities 
were seen in ≈10% embryos. However, this effect was sta-
tistically significant (P<0.05); 400 embryos were assessed to 
verify the effect. This demonstrated the effectiveness of the 
FKBPL antiangiogenic activity across species.
We also investigated the function of zfkbpl during zebrafish 
embryonic development by microinjection of zfkbpl-targeted 
morpholinos (MO). Injection of splice and translation block-
ing MOs (UTR MO), leading to formation of a nonfunctional 
Fkbpl protein impaired the formation of the dorsal longitudi-
nal anastomotic vessels and intersegmental vessel in ≈85% of 
the injected embryos at 48 hpf (Figure 6B and 6C; P=0.006 for 
Figure 5. Lewis lung carcinoma tumor implanted in Fkbpl heterozygous mice demonstrated increased growth rate and angiogenesis in 
comparison to tumors grown in Fkbpl+/+ mice. Growth rate of tumors (A) and survival curves (B), defined as tumors >600 mm3 implanted 
in Fkbpl+/+, Fkbpl+/neo, Fkbpl+/− mice. Quantification of vessels numbers (C) and photomicrographs of images of CD31-stained tumors sec-
tions (D). Lewis lung carcinoma (LLC) tumors were intradermally implanted in the mice and tumor volume measured every 2 days. Tumors 
were excised ≥600 mm3, formalin-fixed, and subjected to immunohistochemistry for CD31. Data points are mean±SEM. n≥3. *P<0.05, 
**P<0.01, ***P<0.001 (1-way ANOVA, Tukey multiple comparison post tests).
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UTR MO and P=0.01 for splice MO). Interestingly, this also 
reduced the number of vessels that form the caudal vein, making 
it look thinner. This vessel inhibition with zfkbpl knockdown is 
contrary to the earlier findings of enhanced angiogenesis with 
loss of one allele in our mouse model and could possibly be 
as a result of levels of Fkbpl. Conditional Fkbpl−/− KO models 
could help further identify any possible dosage-related effects 
that FKBPL might have. Notably, the UTR control MO and 
splice control MO did not alter the vasculature significantly 
(Figure 6B and 6C). Although the splice MO was clearly effec-
tive in the inhibition of zebrafish vasculature, the window of 
effective concentration was, however, close to that of the off-
target curling of the tail. We therefore show the clearer UTR 
MO data images in Figure 6D. The major trunk and tail vessels 
(DA and CV) were not disrupted. Co-injection of hFKBPL 
mRNA with the UTR and splice MO rescued the phenotype in 
≤91% of splice MO (P=0.002) and 83% of UTR MO–injected 
embryos (P=0.01; Figure 6B and 6C). The rescue of vascular 
disruption was also obtained with either full length N or C 
terminal hFKBPL mRNA. Interestingly, the vascular disrupt-
ing effects of fkbpl UTR MO were not seen in the presence of 
a zcd44 MO (Figure 6C), supporting the dependency of Fkbpl 
on Cd44. This suggests that zFkbpl is also secreted, exerting 
its effect in a CD44-dependant outside-in signaling that we 
have previously reported for human cells. No effect of zcd44 
MO was seen in any of the injected embryos, and CD44 UTR 
MO control served as negative control. The vasculature did not 
seem altered in 24-hpf injected embryos.
Discussion
FKBPL is emerging as an important anticancer protein hav-
ing intra- and extracellular roles in tumor and endothelial 
Figure 6. FK506-binding protein like (FKBPL) regulates vessel development in zebrafish embryos (A). Vessel quantification of 72 hpf 
embryos microinjected with AD-01 (1.3 pmol), demonstrating the inhibition of the intersegmental vessel (ISV) development. B and C, 
Graphs demonstrating a significant reduction in the number of embryos with normal vessels after injection of the Splice MO (B) and UTR 
MO (C), and significant phenotype rescue after coinjection of full length, N or C terminal hFKBPL mRNA in a Cd44-dependent manner. 
Embryos showing intact ISV formation at the indicated time points are defined as normal embryos in the quantification. Data points are 
mean±SEM. n≥3. *P<0.05, **P<0.01, ***P<0.001 (1-way ANOVA, Tukey multiple comparison post tests). D, Photomicrographs of 48 hpf 
embryos injected with control MO/zfkbpl MO (UTR) showing the disrupted vasculature; arrows indicate the trunk and tail vessels, and this 
was rescued by expression of full length hFKBPL mRNA. All the images are lateral views, anterior toward left.
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cells.10,14 Although FKBPL mediates its intracellular roles pre-
dominantly via its interaction with other proteins, facilitated 
by its conserved TPR domain,9,11 its antiangiogenic effects 
are mediated through secretion and inside out signaling via 
the CD44 pathway.12 FKBPL is a nonconventional secreted 
protein lacking the signal peptide domain associated with pro-
teins secreted via the golgi-ER pathway.17 We have previously 
reported that the antimigratory activity of FKBPL is reversed 
in the presence of a blocking antibody targeted to its antian-
giogenic site, highlighting the role of the secreted protein in 
migration and angiogenesis.12 Here we observe that FKBPL 
is mainly secreted from endothelial and fibroblast cell lines 
(10- to 15-fold higher than cancer or epithelial cells), the 2 
cell types with angiogenic and wound healing functions18,19 
Importantly, FKBPL secretion is downregulated under 
hypoxia, a principal angiogenic stimulus that upregulates a 
range of angiogenic cytokines.20 This hypoxia-mediated regu-
lation of FKBPL occurs specifically at the secreted level as 
the intracellular protein and RNA levels remain unaffected, 
further supporting the role of extracellular FKBPL in the 
regulation of angiogenesis. Interestingly, although VEGF is 
the proximate central angiogenic factor to hypoxia, regulating 
other downstream angiogenic events factors, it did not have 
any effect on FKBPL’s intra- or extracellular levels. Other 
angiogenic cytokines, IL-8 and FGF, did not affect FKBPL 
levels either. This further strengthens our hypothesis that 
FKBPL is upstream or independent of these pathways.
Although the role of FKBPL on tumor angiogenesis has 
been extensively investigated; its endogenous role in physi-
ological or developmental angiogenesis has not yet been elu-
cidated. Here we interrogated this function by developing an 
Fkbpl KO mouse model. The Fkbpl allele was targeted at the 
exon 2 region, leading to the complete deletion of the Fkbpl 
open reading frame (ORF), resulting in successful generation 
of mice heterozygous for Fkbpl. Attempts at generation of 
homozygous Fkbpl mice using Fkbpl+/neo or Fkbpl+/− crosses 
were unsuccessful, suggesting that the homozygous Fkbpl KO 
is embryonically lethal, potentially because of its important 
and essential role in murine development. Other angiogenic 
regulators demonstrating embryonic lethality are VEGF-A,21 
DLL4,22 the Notch pathway genes, and angiopoietin,23 whereas 
bFGF-null mice do not develop vascular defects, and inactiva-
tion of PlGF or VEGF-B genes does not result in any major 
development abnormalities.24 Nevertheless, modest overex-
pression of VEGF results in excessive angiogenesis in mice, 
leading to severe abnormalities and embryonic lethality.25 
Using timed matings, we identified the Fkbpl KO–mediated 
embryonic lethality occurred at ≤E8.5. This corresponds with 
early vasculogenesis in the mouse embryo, which commences 
around E7.026 when angioblasts entering the embryo aggre-
gate to form major vessels.
Further analysis of both Fkbpl heterozygous strains for 
expression of FKBPL mRNA and secreted levels corre-
lated with the genotype and confirmed the absence of dos-
age compensation in these mice. We therefore proceeded to 
characterize the embryonic development of Fkbpl+/neo mice. 
In accordance with the qPCR results, confocal microscopy 
images of intersomatic blood vessels (at comparable level 
of the body axis) indicate that E11.5 Fkbpl+/neo mice showed 
significantly reduced levels of FKBPL compared with E11.5 
Fkbpl+/+. FKBPL was strongly expressed in cells present in the 
lumen of blood vessels resembling primitive nucleated eryth-
roblasts.27 This would seem to be consistent with its function 
as an angiogenesis regulator. The fenestrated morphology of 
vessels with clustering of FKBPL+ cells in Fkbpl+/neo embryo 
sections possibly indicate finer, easily distorted vessels, poor 
circulation, or a decreased number of FKBPL+ cells. The 
distinct morphology of the endothelial cells in Fkbpl+/neo  
embryos is consistent with the FKBPL-mediated effects on 
the cytoskeleton and the actin-tubulin dynamics as previously 
observed.12 These abnormalities in the embryonic vascula-
ture, however, did not affect subsequent development, and 
no abnormality was observed in the histology of the organs. 
However, possible effects on longevity and age-related abnor-
malities remain to be investigated. To further evaluate the role 
of FKBPL in angiogenesis, induced models of angiogenesis 
were used. Ex vivo, aortae excised from Fkbpl+/+ mice demon-
strated ordered sprouting; however, this process appeared to 
be significantly enhanced in Fkbpl+/neo, and vessel sprouts were 
highly branched and numerous. The increase in sprouting in 
FKBPL-deficient vessels is most likely because of its effect 
on endothelial cell migration rather than enhanced endothelial 
cell proliferation; our previous studies clearly demonstrate that 
FKBPL or its peptide derivatives do not affect endothelial cell 
viability.10 The reversal of this enhanced sprouting obtained in 
Fkbpl+/neo aortae treated with AD-0110 supported the specificity 
of its antiangiogenic activity. Furthermore, the additive effect 
of Fkbpl+/neo vessel sprouting obtained with VEGF treatment 
supports the hypothesis that FKBPL-mediated effects are 
independent of the VEGF pathway.
In an in vivo sponge assay, the increased vessel recruitment 
observed in Fkbpl+/neo and Fkbpl+/− mice confirmed their pro-
angiogenic phenotype in vivo. The heterozygote vessels in 
the sponges appeared leaky on visual quantification. Irregular 
and increased vessel number was also observed in the Lewis 
lung carcinoma tumors grown in Fkbpl+/neo or Fkbpl+/− mice. 
Clearly, stromal FKBPL appeared to play a regulatory role in 
tumor growth and vascular development in this model; tumors 
in Fkbpl heterozygote mice grew faster with an increase in 
tumor angiogenesis. The role of tumor microenvironment in 
the regulation of tumor growth is indeed critical and regulates 
key processes of angiogenesis, metastasis, and cancer stem cell 
differentiation and is one of the hallmarks of tumorigenesis.28
To understand the mechanism of angiogenesis and its 
role in development, we used the zebrafish (Danio rerio) 
model. The FKBPL homologue (30% similarity) in zebrafish 
showed a similar structure in the C-terminal TPR domains, 
characteristic of the immunophilin family.11 The inhibition 
of intersegmental vessel formation in the zebrafish embryos 
with AD-01 treatment correlates to its well-characterized 
antiangiogenic effects observed earlier,10,12 as well as in this 
study. The endogenous role of Fkbpl in the fish model evalu-
ated using morpholinos targeting the zfkbpl splice junction 
and the UTR resulted in an impairment of dorsal longitu-
dinal anastomotic vessels and intersegmental vessel forma-
tion rescued with coinjection of either full length or N or C 
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terminal hFKBPL mRNA. This indicated the conservation of 
FKBPL function across species. Interestingly, this function 
was dependent on zCd44 as the zfkbpl MO-mediated vessel 
impairment was abrogated in the zcd44 morphant zebrafish 
embryos. This confirms our earlier studies on the CD44-
dependent effect of FKBPL on migration of tumor and endo-
thelial cells,10,12 further strengthening the role of zCd44 as 
zFkbpl’s extracellular membrane target. The disruption in the 
vessels suggests that complete loss of zFkbpl inhibits vessel 
formation or perhaps formation of nonrobust vessels because 
of loss of its antiangiogenic activity. Indeed, tight regulation 
of VEGF is essential for a functional vasculature and devel-
opment; zebrafish studies with Vegf overexpression, as well 
as zvegf morphant embryos, have reported defective vascula-
ture, resulting in pericardial edema and abnormal blood cell 
accumulation.29 Alternatively, the complete loss of FKBPL, 
as well as excess FKBPL (overexpression and exogenous 
addition10,12), may have inhibitory effects on angiogenesis. 
Dosage-dependant effects have been observed for other reg-
ulators of angiogenesis. For example, loss of one allele of 
DLL4 results in excessive and nonproductive angiogenesis,30 
whereas Dll4 overexpressing and Dll4 KO mice both show 
impaired wound healing and antiangiogenic effects.31 Similar 
effects have been reported with focal adhesion kinase–defi-
cient mice, where loss of one allele promoted angiogenesis 
and loss of both alleles inhibited it.32 Similarly, RGD (argi-
nylglycylaspartic acid) mimetics that target integrins show 
differential dosage-dependent effects on angiogenesis.33 
Further studies using conditional Fkbpl−/− mice to allow both 
the spatial and temporal ablation of FKBPL expression will 
be required to further elucidate the effect of FKBPL dosage.
Although the data presented here strongly suggest a role 
for FKBPL as a potent antiangiogenic mediator, our previous 
data also supports a role for FKBPL as an intracellular regu-
lator of estrogen receptor signaling through its association 
with Hsp90.13 Therefore, the FKBPL-mediated effects on the 
embryonic lethality, the differences in our mouse and zebraf-
ish data and perhaps why tumor growth rates in our FKBPL-
deficient mice are higher, might also suggest a role for 
FKBPL-mediated regulation of estrogen receptor signaling. 
Indeed, the regulation of angiogenesis by estrogens and sig-
naling via the Notch pathway has been previously reported.34 
However, this is beyond the scope of the current article and 
would need to be further evaluated in future studies.
In conclusion, we have identified an essential role for 
FKBPL in murine embryonic and zebrafish vascular develop-
ment. Loss of one Fkbpl allele in mice gives rise to a strong 
proangiogenic phenotype. Thus, deregulation of FKBPL 
levels could have serious implications for diseases associ-
ated with aberrant angiogenesis, widening the scope for the 
FKBPL-based clinical candidate, ALM201.
Acknowledgments
We thank the staff at the Biological Resource Unit (BRU) for their 
help and support for all in vivo experiments, QUB, The Northern 
Ireland-Molecular Pathology Laboratory (NI-MPL), QUB for their 
help with the processing and scanning of tissue sections, and Ann 
Marie Higgins for her assistance with the vessel quantification during 
her MPharm level 4 project at the School of Pharmacy, QUB.
Sources of Funding
This project was supported through a Biotechnology and Biological 
Sciences Research Council grant awarded to T. Robson (BB/
I006958/1) covering salaries for A. Yakkundi, I. Hernández-Negrete, 
O. Lyubomska, M. Hanna. R. Bennett was supported by a Department 
of Employment and Learning-PhD studentship. The Northern 
Ireland-Molecular Pathology Laboratory is supported by Cancer 
Research UK, the Experimental Cancer Medicine Centre Network, 




 1. Swift MR, Weinstein BM. Arterial-venous specification dur-
ing development. Circ Res. 2009;104:576–588. doi: 10.1161/
CIRCRESAHA.108.188805.
 2. Wietecha MS, DiPietro LA. Therapeutic approaches to the regulation of 
wound angiogenesis. Adv Wound Care (New Rochelle). 2013;2:81–86. 
doi: 10.1089/wound.2011.0348.
 3. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–
660. doi: 10.1038/nm0603-653.
 4. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat 
Rev Drug Discov. 2007;6:273–286. doi: 10.1038/nrd2115.
 5. Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond 
VEGF inhibition: a journey from antiangiogenic single-target to broad-
spectrum agents. Cancer Treat Rev. 2014;40:548–557. doi: 10.1016/j.
ctrv.2013.11.009.
 6. Kieran MW, Kalluri R, Cho YJ. The VEGF pathway in cancer and disease: 
responses, resistance, and the path forward. Cold Spring Harb Perspect 
Med. 2012;2:a006593. doi: 10.1101/cshperspect.a006593.
 7. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel 
RS. Accelerated metastasis after short-term treatment with a potent inhibi-
tor of tumor angiogenesis. Cancer Cell. 2009;15:232–239. doi: 10.1016/j.
ccr.2009.01.021.
 8. Robson T, Joiner MC, Wilson GD, McCullough W, Price ME, Logan 
I, Jones H, McKeown SR, Hirst DG. A novel human stress response-
related gene with a potential role in induced radioresistance. Radiat Res. 
1999;152:451–461.
 9. McKeen HD, McAlpine K, Valentine A, Quinn DJ, McClelland K, Byrne 
C, O’Rourke M, Young S, Scott CJ, McCarthy HO, Hirst DG, Robson 
T. A novel FK506-like binding protein interacts with the glucocorti-
coid receptor and regulates steroid receptor signaling. Endocrinology. 
2008;149:5724–5734. doi: 10.1210/en.2008-0168.
 10. Valentine A, O’Rourke M, Yakkundi A, et al. FKBPL and peptide deriva-
tives: novel biological agents that inhibit angiogenesis by a CD44-
dependent mechanism. Clin Cancer Res. 2011;17:1044–1056. doi: 
10.1158/1078-0432.CCR-10-2241.
 11. Robson T, James IF. The therapeutic and diagnostic potential of FKBPL; 
a novel anticancer protein. Drug Discov Today. 2012;17:544–548. doi: 
10.1016/j.drudis.2012.01.002.
 12. Yakkundi A, McCallum L, O’Kane A, Dyer H, Worthington J, McKeen 
HD, McClements L, Elliott C, McCarthy HO, Hirst DG, Robson T. The 
anti-migratory effects of FKBPL and its peptide derivative, AD-01: regu-
lation of CD44 and the cytoskeletal pathway. PLoS One. 2013;8:e55075. 
doi: 10.1371/journal.pone.0055075.
 13. McKeen HD, Byrne C, Jithesh PV, Donley C, Valentine A, Yakkundi A, 
O’Rourke M, Swanton C, McCarthy HO, Hirst DG, Robson T. FKBPL 
regulates estrogen receptor signaling and determines response to endo-
crine therapy. Cancer Res. 2010;70:1090–1100. doi: 10.1158/0008-5472.
CAN-09-2515.
 14. McKeen HD, Brennan DJ, Hegarty S, Lanigan F, Jirstrom K, Byrne 
C, Yakkundi A, McCarthy HO, Gallagher WM, Robson T. The emerg-
ing role of FK506-binding proteins as cancer biomarkers: a focus 
on FKBPL. Biochem Soc Trans. 2011;39:663–668. doi: 10.1042/
BST0390663.
 15. McClements L, Yakkundi A, Papaspyropoulos A, Harrison H, Ablett MP, 
Jithesh PV, McKeen HD, Bennett R, Donley C, Kissenpfennig A, McIntosh 
S, McCarthy HO, O’Neill E, Clarke RB, Robson T. Targeting treatment-
resistant breast cancer stem cells with FKBPL and its peptide derivative, 
AD-01, via the CD44 pathway. Clin Cancer Res. 2013;19:3881–3893. doi: 
10.1158/1078-0432.CCR-13-0595.
854  Arterioscler Thromb Vasc Biol  April 2015
 16. Schuermann A, Helker CS, Herzog W. Angiogenesis in zebrafish. Semin 
Cell Dev Biol. 2014;31:106–114. doi: 10.1016/j.semcdb.2014.04.037.
 17. Maxwell CA, McCarthy J, Turley E. Cell-surface and mitotic-spin-
dle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci. 
2008;121(Pt 7):925–932. doi: 10.1242/jcs.022038.
 18. Enzerink A, Vaheri A. Fibroblast activation in vascular inflammation. J Thromb 
Haemost. 2011;9:619–626. doi: 10.1111/j.1538-7836.2011.04209.x.
 19. Wacker A, Gerhardt H. Endothelial development taking shape. Curr Opin 
Cell Biol. 2011;23:676–685. doi: 10.1016/j.ceb.2011.10.002.
 20. Yang Y, Sun M, Wang L, Jiao B. HIFs, angiogenesis, and cancer. J Cell 
Biochem. 2013;114:967–974. doi: 10.1002/jcb.24438.
 21. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel devel-
opment and lethality in embryos lacking a single VEGF allele. Nature. 
1996;380:435–439. doi: 10.1038/380435a0.
 22. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, 
Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G, Yancopoulos GD. 
Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due 
to major defects in arterial and vascular development. Proc Natl Acad Sci 
U S A. 2004;101:15949–15954. doi: 10.1073/pnas.0407290101.
 23. Karamysheva AF. Mechanisms of angiogenesis. Biochemistry (Mosc). 
2008;73:751–762.
 24. Ferrara N. Vascular endothelial growth factor: basic science and clinical 
progress. Endocr Rev. 2004;25:581–611. doi: 10.1210/er.2003-0027.
 25. Miquerol L, Langille BL, Nagy A. Embryonic development is disrupted 
by modest increases in vascular endothelial growth factor gene expression. 
Development. 2000;127:3941–3946.
 26. Knudsen TB, Kleinstreuer NC. Disruption of embryonic vascular devel-
opment in predictive toxicology. Birth Defects Res C Embryo Today. 
2011;93:312–323. doi: 10.1002/bdrc.20223.
 27. Fraser ST, Isern J, Baron MH. Maturation and enucleation of primitive 
erythroblasts during mouse embryogenesis is accompanied by changes in 
cell-surface antigen expression. Blood. 2007;109:343–352. doi: 10.1182/
blood-2006-03-006569.
 28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144:646–674. doi: 10.1016/j.cell.2011.02.013.
 29. Liang D, Chang JR, Chin AJ, Smith A, Kelly C, Weinberg ES, Ge R. The 
role of vascular endothelial growth factor (VEGF) in vasculogenesis, 
angiogenesis, and hematopoiesis in zebrafish development. Mech Dev. 
2001;108:29–43.
 30. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito 
R, Djokovic D, Borges C, Ley EJ, Duarte A, Gill PS. Inhibition of Dll4-
mediated signaling induces proliferation of immature vessels and results 
in poor tissue perfusion. Blood. 2007;109:4753–4760. doi: 10.1182/
blood-2006-12-063933.
 31. Trindade A, Djokovic D, Gigante J, Badenes M, Pedrosa AR, Fernandes 
AC, Lopes-da-Costa L, Krasnoperov V, Liu R, Gill PS, Duarte A. Low-
dosage inhibition of Dll4 signaling promotes wound healing by inducing 
functional neo-angiogenesis. PLoS One. 2012;7:e29863. doi: 10.1371/
journal.pone.0029863.
 32. Kostourou V, Lechertier T, Reynolds LE, Lees DM, Baker M, Jones 
DT, Tavora B, Ramjaun AR, Birdsey GM, Robinson SD, Parsons M, 
Randi AM, Hart IR, Hodivala-Dilke K. FAK-heterozygous mice display 
enhanced tumour angiogenesis. Nat Commun. 2013;4:2020. doi: 10.1038/
ncomms3020.
 33. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and 
angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. 
Nat Med. 2009;15:392–400. doi: 10.1038/nm.1941.
 34. Caliceti C, Aquila G, Pannella M, Morelli MB, Fortini C, Pinton P, 
Bonora M, Hrelia S, Pannuti A, Miele L, Rizzo P, Ferrari R. 17β-estradiol 
enhances signalling mediated by VEGF-A-delta-like ligand 4-notch1 axis 
in human endothelial cells. PLoS One. 2013;8:e71440. doi: 10.1371/jour-
nal.pone.0071440.
Secreted FK506-binding protein like (FKBPL) and its peptide derivatives inhibit cell migration and tumor angiogenesis by targeting CD44. We 
report that secretion of FKBPL is downregulated under the proangiogenic stimulus of hypoxia, independent of VEGF pathway. Using knockout 
mice and zebrafish models, we have established that FKBPL is essential for early embryonic development. Moreover, it is a critical regula-
tor of angiogenic process; loss of one Fkbpl allele results in enhanced angiogenesis in experimental and tumor disease models. Modulation 
of FKBPL levels can therefore be exploited for therapeutic purposes. Reduced FKBPL levels, leading to enhanced angiogenesis, implicates 
a possible role in diseases other than cancer, such as cardiovascular and wound healing disease, thus extending the therapeutic utility of 
targeting FKBPL. FKBPL also has potential as a biomarker of angiogenesis and its secreted levels, offering ease of detection. This study 
therefore provides further support in enhancing the therapeutic and biomarker potential of FKBPL.
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